{"product_id":"epigenetics-market-by-offering-kits-reagents-instruments-software-method-dna-methylation-pcr-chromatin-analysis-histone-rna-modification-application-oncology-non-oncology-end-user-pharma-academics-hospitals-global-forecast-to-2030","title":"Epigenetics Market by Offering (Kits, Reagents, Instruments, Software) Method (DNA Methylation, PCR, Chromatin Analysis, Histone, RNA Modification), Application (Oncology, Non-oncology) End User (Pharma, Academics, Hospitals) – Global Forecast to 2030","description":"\u003cp\u003eThe Epigenetics Market by Offering (Kits, Reagents, Instruments, Software) Method (DNA Methylation, PCR, Chromatin Analysis, Histone, RNA Modification), Application (Oncology, Non-oncology) End User (Pharma, Academics, Hospitals) – Global Forecast To 2030\u003cbr\u003e\nThe epigenetics market is expected to reach $5.47 billion by 2030, at a CAGR of 15.7% from 2023 to 2030.\u003c\/p\u003e\n\n\u003cp\u003eSucceeding extensive secondary and primary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of the epigenetics market is driven by the rising incidence of chronic diseases due to growth in the aging population, the increasing prevalence of cancer, rising pharmaceutical R\u0026amp;D expenditures, the increasing focus on epigenetics in drug discovery \u0026amp; development, and the declining costs of genome sequencing. However, the lack of skilled professionals restrains the growth of this market.\u003c\/p\u003e\n\n\u003cp\u003eThe growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market. However, standardization concerns associated with epigenetics procedures and the limited applications of epigenetics in toxicology are major challenges to market growth.\u003c\/p\u003e\n\n\u003cp\u003eBased on offering, the epigenetics market is segmented into kits \u0026amp; reagents, instruments and accessories, software and services. The kits \u0026amp; reagents segment is expected to grow at the fastest CAGR during the forecast period. The frequent and repetitive use of kits and reagents and the growing prevalence of chronic diseases are the major factors responsible for segment growth.\u003c\/p\u003e\n\n\u003cp\u003eBased on method, the epigenetics market is segmented into DNA methylation, histone modification, RNA modification, polymerase chain reaction (PCR), chromatin analysis, sonication, and other methods. In 2023, the DNA methylation segment is expected to account for the largest share of the market. DNA methylation is an epigenetic mechanism that involves transferring a methyl group onto the C5 position of cytosine to form 5-methylcytosine. This process regulates gene expression by promoting or inhibiting the binding of transcription factors to DNA. Thus, it is useful in studying epigenetic changes in an organism. The increasing prevalence of cancer, technological advancements in PCR and sequencing, and the high focus on reducing costs associated with lengthy research and product approval processes support the segment’s large share.\u003c\/p\u003e\n\n\u003cp\u003eBased on application, the epigenetics market is segmented into oncology and non-oncology. In 2023, the oncology segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the high burden of cancer, the high focus on R\u0026amp;D regarding cancer, and the growing demand for precision oncology.\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, the epigenetics market is segmented into pharmaceutical \u0026amp; biotechnology companies, academic \u0026amp; research institutes, and hospitals \u0026amp; diagnostic laboratories. In 2023, the pharmaceutical \u0026amp; biotechnology companies segment is expected to account for the largest share of the market. The segment’s large share is attributed to the rising demand for research-related products, the increasing incidence of chronic diseases, pharmaceutical \u0026amp; biotechnology companies’ rising R\u0026amp;D expenditures, technological advancements in epigenetics, and the introduction of new epigenetics products for chronic and rare diseases.\u003c\/p\u003e\n\n\u003cp\u003eAn in-depth analysis of the geographical scenario of the epigenetics market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East \u0026amp; Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register the highest CAGR during the forecast period. The market growth in this region is attributed to government initiatives for genetic diseases, growing cancer incidence, rising geriatric population, rapid rise in the prevalence of chronic diseases, rising R\u0026amp;D spending, and increasing healthcare expenditure.\u003c\/p\u003e\n\n\u003cp\u003eSome of the key players operating in the global epigenetics market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif (U.S.), and Zymo Research Corporation (U.S.).\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report\u003c\/p\u003e\n\n\u003cp\u003eEpigenetics Market Assessment, by OfferingKits \u0026amp; ReagentsKits \u0026amp; AssaysAntibodiesProteins \u0026amp; EnzymesOther Reagents(Other reagents include buffers, controls, beads, histones, master mixes, and nuclease-free water)ServicesSoftwareEpigenetics Market Assessment, by MethodDNA MethylationBisulfite ConversionHigh-resolution Melt (HRM) AnalysisImmunoprecipitationOther DNA Methylation Methods(Other DNA methylation methods include activity\/inhibition assays, methylated DNA quantification, and methylated DNA amplification)Histone ModificationRNA ModificationPolymerase Chain ReactionChromatin AnalysisSonicationOther Methods(Other methods include in vitro DNA-protein interactions, DNA demethylation, and miRNA analysis)Epigenetics Market Assessment, by ApplicationOncologyNon-oncologyEpigenetics Market Assessment, by End UserPharmaceutical \u0026amp; Biotechnology CompaniesAcademic \u0026amp; Research InstitutesHospitals \u0026amp; Diagnostic LaboratoriesEpigenetics Market Assessment, by GeographyNorth AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalySpainRest of EuropeAsia-PacificChinaJapanIndiaRest of Asia-PacificLatin AmericaMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eEpigenetics Market - Report SummaryReport MetricsDetailsYears Considered2021 - 2030Base Year2022Forecast Period2023-2030Page Count208Units ReferencedValue (USD Million)Segments\/Key TopicsMarket by Offering, Method, Application, and End UserRegions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East \u0026amp; AfricaKey Companies MentionedThermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif (U.S.), and Zymo Research Corporation (U.S.).\u003c\/p\u003e\n\n\u003cp\u003eFAQs About the Report\u003c\/p\u003e\n\n\u003cp\u003eWhat is the focus of the epigenetics market study?\u003c\/p\u003e\n\n\u003cp\u003eThe epigenetics market report covers market sizes \u0026amp; forecasts for offering, method, application, and end user. The report includes the value analysis of various segments and subsegments of the epigenetics market at the country \u0026amp; regional level.\u003c\/p\u003e\n\n\u003cp\u003eWhat is the revenue generated from the sales of epigenetic products across the globe? At what rate is the demand expected to grow for the next 5–7 years?\u003c\/p\u003e\n\n\u003cp\u003eThe epigenetics market is projected to reach $5.47 billion by 2030, at a CAGR of 15.7% from 2023 to 2030.\u003c\/p\u003e\n\n\u003cp\u003eWhich type of offering segment is estimated to hold the major share of the market in 2023?\u003c\/p\u003e\n\n\u003cp\u003eThe kits \u0026amp; reagents management segment is estimated to account for the largest share of the epigenetics market in 2023 due to the increasing prevalence of various chronic diseases, such as cancer, and the frequent \u0026amp; repetitive usage of kits \u0026amp; reagents for epigenetic analyses.\u003c\/p\u003e\n\n\u003cp\u003eWhich method segment is projected to gain more traction in the epigenetics market?\u003c\/p\u003e\n\n\u003cp\u003eThe DNA Methylation segment is projected to gain more traction in the epigenetics market.\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the epigenetics market?\u003c\/p\u003e\n\n\u003cp\u003eThe growth of the epigenetics market is driven by the rising incidence of chronic diseases due to growth in the aging population, the increasing prevalence of cancer, rising pharmaceutical R\u0026amp;D expenditures, the increasing focus on epigenetics in drug discovery \u0026amp; development, and the declining costs of genome sequencing. Moreover, the growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market.\u003c\/p\u003e\n\n\u003cp\u003eWho are the major players operating in the epigenetics market?\u003c\/p\u003e\n\n\u003cp\u003eThe key players operating in the epigenetics market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif (U.S.), and Zymo Research Corporation (U.S.).\u003c\/p\u003e\n\n\u003cp\u003eWhich countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?\u003c\/p\u003e\n\n\u003cp\u003eEmerging economies in the Asia-Pacific region, including China and India, are expected to offer growth opportunities for the players operating in this market. The growing geriatric population, rising R\u0026amp;D funding from both the government and private pharmaceutical companies, technological advancements, and growing prevalence of noncommunicable diseases likely drive the growth of this market.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 208 Pages \/ MCW16232398","offer_id":47647503941938,"sku":null,"price":5010.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/epigenetics-market-by-offering-kits-reagents-instruments-software-method-dna-methylation-pcr-chromatin-analysis-histone-rna-modification-application-oncology-non-oncology-end-user-pharma-academics-hospitals-global-forecast-to-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}